Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712317 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL28854869 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL14989469 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL28645682 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL14989468 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL16554025 | 0.97 | CA1 (0.45) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL16554022 | 0.97 | CA1 (0.45) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL16566219 | 0.92 | ALDH1A1 (0.43) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL23819216 | 0.91 | BTN3A1 (0.44) | ALDH1A1CA1CA2BCHEACHE | |
| SCHEMBL13469579 | 0.90 | ALDH1A1 (0.47) | ALDH1A1CA1CA2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493480-A | Preparation and analysis method of Reidesciclovir isomer | 南京正大天晴制药有限公司 | 2021-10-12 | — | — | CN | claimed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-115403626-A | Novel crystalline forms | 吉利德科学公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220354873-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| CN-110636884-B | Novel crystalline forms | 吉利德科学公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-4036099-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114191438-A | Methods of treating filoviridae virus infections | 吉利德科学公司 | 2022-03-18 | — | — | CN | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3212175-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3212174-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016069827-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069825-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069826-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | ALDH1A1 1567/4885CA1 4736/4885CA2 4682/4885 |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | ALDH1A1 1121/4885CA1 4046/4885CA2 3661/4885 |
| US-20220354873-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | ALDH1A1 1567/4885CA1 4736/4885CA2 4682/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | ALDH1A1 4115/4885CA1 3198/4885CA2 1859/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | ALDH1A1 1121/4885CA1 4046/4885CA2 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.